Typhoid Fever Vaccines Market Synopsis:
Typhoid Fever Vaccines Market Size Was Valued at USD 3.41 Billion in 2023, and is Projected to Reach USD 10.00 Billion by 2032, Growing at a CAGR of 12.7% From 2024-2032.
The market for typhoid fever vaccines plays a pivotal role towards meeting the global health challenge posed by typhoid fever, a potentially fatal disease caused by Salmonella typhi bacteria. It continues to be rampant in most developing nations where proper hygiene and sanity is never practiced hence causing much morbidity and mortality particularly among children. Eradication remains a crucial part of controlling typhoid fever and its prevention is through vaccination. The existence of live attenuated and polysaccharide vaccines has diversified the approaches to immunization to enhance the general health within the endemic zones.
New developments in the production and design of vaccines have served to strengthen the prospect of enhanced efficacy and safety of typhoid vaccines. Efforts like development of a new age vaccine like the typhoid conjugate vaccine has shown greater immunogenicity and more long-term protection than previous vaccines. Since WHO has recommended the use of TCV in vaccination programmes there has been increased call for the TCV to be incorporated into the routine immunisation schedules in areas of high risk. The rising awareness about the availability of vaccines, favourable governments policies, and supportive measures will contribute to the global market expansion of typhoid fever vaccines.• Still some negative factors are noted here Some of the challenges affecting this market are; low awareness of the diseases especially typhoid fever as well as the benefits of the vaccine, problems associated with storing and distributing the vaccines especially in developing countries.ogenicity and longer-lasting protection compared to older formulations. With the World Health Organization (WHO) endorsing the use of TCV in vaccination programs, there is a growing push for its incorporation into routine immunization schedules in high-risk areas. This increasing recognition of the importance of vaccination, along with supportive government policies and initiatives, is expected to drive the growth of the typhoid fever vaccines market.
Despite these positive trends, the market faces several challenges, including the lack of awareness about typhoid fever and vaccination in certain regions, along with logistical issues related to vaccine distribution and storage in developing countries. However, constant threats from development of competition from other vaccines and possible evolution of antibiotic- resistant strains of Salmonella typhi militates against disease control measures. Nevertheless, there are many opportunities: with the growth of global health funding, implementing partnerships with NGOs, as well as campaigns to enhance the vaccination rates in members states with the existing epidemics. Since the efforts of the immunization campaigns persist in the global society there is potential of growth in the typhoid fever vaccines market which will partially help address the issue of disease occurrence and enhance people’s health globally.
Typhoid Fever Vaccines Market Trend Analysis:
Increasing Adoption of Typhoid Conjugate Vaccines (TCVs)
-
An important market trend is that TCVs are rapidly being incorporated in programs to fight typhoid fever, especially in LMICs. THCVs are superior to conventional vaccines mainly because they are immunogenic, longer enduring and can be used on children with as young as six months. The WHO has included TCVs in its toolbox as a lead approach to control typhoid fever, a move that has seen it be adopted in national immunization programmes in several high-endemic areas. These trends should expand linguistic coverage considerably and greatly decrease the reported incidence of typhoid fever around the world, enhancing the representativeness of public health.
Expansion of Vaccination Programs and Public Awareness Initiatives
-
Other trends include increase in vaccination agendas along with sensitization activities for the general public, to popularize typhoid vaccination. Bureaucratic and non-governmental organizations, as well as the health organizations are coming together to popularize the immunization in specific regions affected by the disease. Herd immunity activities concentrate on increasing vaccine availability, strengthening health care systems, and raising awareness of the disease’s mode of transmission, signs and preventive measures. The increased awareness and access to the vaccine should result from these efforts in a demand for the typhoid vaccines and subsequent decrease of incidence and mortality associated with typhoid fever.
Typhoid Fever Vaccines Market Segment Analysis:
Typhoid Fever Vaccines Market is Segmented on the basis of By Type, Route of Administration, End-Users, Distribution Channel, Region.
By Type, Live Attenuated Vaccine segment is expected to dominate the market during the forecast period
-
The typhoid fever vaccines market is classified, based on the type into live attenuated vaccines; monovalent typhoid vaccines; capsular polysaccharide vaccines; conjugate vaccines; and others. In entry and replication viruses like the Ty21a vaccine stimulates a relatively long-term immunity and given orally. Monovalent typhoid vaccines are vaccines developed particularly for the prevention of Salmonella typhi infection; they are very useful in endemic areas.
- ViCPS is an example of a capsular polysaccharide vaccine of which confers immunity after a single injection; however, booster doses might be necessary. Therefore, conjugate vaccines, as done in the newly developed typhoid conjugate vaccines (TCV), merge the polysaccharide antigens to a carrier protein for a more effective immunity and long-lasting immunity. The availability of vaccines in the market is varied hence there can be flexible vaccination schedule to be accorded to those vulnerable groups as a way of enhancing the success rate of the war against typhoid fever.
Distribution Channel, Online Pharmacy segment expected to held the largest share
-
The current distribution platforms of the typhoid fever vaccines include the hospital pharmacies, retail pharmacy shops, online pharmacy stores, and other other specialty channels. This has encouraged hospital pharmacies to give out vaccines themselves during outpatient services, hospital trips, and other appointments so as to provide immediate services for patients who need to be vaccinated. Retail pharmacies make their own contribution especially by administering vaccines to the general public during vaccine campaigning or health promotion programs.
- In this age where the use of the internet is fully integrated into people’s lifestyles, using online facilities is becoming popular especially because through these, people can order vaccines and related health products without having to move from home. Other distribution chanels may be centers that offer complete health services in the affected endemic areas as well as public health interventions. It is important to spread vaccine coverage in this way and meet public health needs in order to minimally reduce the incidence of typhoid fever.
Typhoid Fever Vaccines Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
-
North America is anticipated to exhibit the highest growth in the global market for typhoid fever vaccines during the forecasting period owing to sound health care facilities and a wide range of immunization activities coupled with a sharp focus on prevention. The region has high awareness of vaccines and supportive polices in the control of infectious diseases including typhoid fever.
- Current innovation and development of vaccines in the North America market from the key industry players are helpful to develop some better and improved vaccines of the world including newer vaccines like TCV. Second, there is rising demand for vaccine among travelers, as the probability of typhoid fever contracts in endemic regions increases with the enhancement of international travel. This paper identifies North America as a critical market for the typhoid fever vaccines due to these factors to beef up its capacity to advance vaccination and improve health outcomes.
Active Key Players in the Typhoid Fever Vaccines Market
-
Amgen Inc. (US)
- AstraZeneca (UK)
- Bharat Biotech (India)
- Bio Farma (Indonesia)
- BIO-MED (India)
- bioMérieux SA (France)
- EMERGENT (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- GlaxoSmithKline plc (UK)
- Johnson & Johnson Private Limited (US)
- Lupin (India)
- Mallinckrodt (US)
- Merck & Co., Inc. (US)
- Mylan N.V. (US)
- Novartis AG (Switzerland)
- Pfizer Inc. (US)
- Sanofi (France)
- Sun Pharmaceutical Industries Ltd. (India)
- Takeda Pharmaceutical Company Limited (Japan)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Others Active Players.
|
Global Typhoid Fever Vaccines Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 3.41 Billion |
|
Forecast Period 2024-32 CAGR: |
12.7% |
Market Size in 2032: |
USD 10.00 Billion |
|
Segments Covered: |
By Type |
|
|
|
Route of Administration |
|
||
|
By End-Users |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Typhoid Fever Vaccines Market by Type
4.1 Typhoid Fever Vaccines Market Snapshot and Growth Engine
4.2 Typhoid Fever Vaccines Market Overview
4.3 Live Attenuated Vaccine
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Live Attenuated Vaccine: Geographic Segmentation Analysis
4.4 Monovalent Typhoid Vaccines
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Monovalent Typhoid Vaccines: Geographic Segmentation Analysis
4.5 Capsular Polysaccharide Vaccines
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Capsular Polysaccharide Vaccines: Geographic Segmentation Analysis
4.6 Conjugate Vaccine
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Conjugate Vaccine: Geographic Segmentation Analysis
4.7 Others)
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Others): Geographic Segmentation Analysis
4.8 Route of Administration (Oral
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Route of Administration (Oral: Geographic Segmentation Analysis
4.9 Parenteral)
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 Parenteral): Geographic Segmentation Analysis
4.10 End-Users (Hospitals
4.10.1 Introduction and Market Overview
4.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.10.3 Key Market Trends, Growth Factors and Opportunities
4.10.4 End-Users (Hospitals: Geographic Segmentation Analysis
4.11 Specialty Clinics
4.11.1 Introduction and Market Overview
4.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.11.3 Key Market Trends, Growth Factors and Opportunities
4.11.4 Specialty Clinics: Geographic Segmentation Analysis
4.12 Homecare
4.12.1 Introduction and Market Overview
4.12.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.12.3 Key Market Trends, Growth Factors and Opportunities
4.12.4 Homecare: Geographic Segmentation Analysis
4.13 Others)
4.13.1 Introduction and Market Overview
4.13.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.13.3 Key Market Trends, Growth Factors and Opportunities
4.13.4 Others): Geographic Segmentation Analysis
4.14
4.14.1 Introduction and Market Overview
4.14.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.14.3 Key Market Trends, Growth Factors and Opportunities
4.14.4 : Geographic Segmentation Analysis
Chapter 5: Typhoid Fever Vaccines Market by Distribution Channel
5.1 Typhoid Fever Vaccines Market Snapshot and Growth Engine
5.2 Typhoid Fever Vaccines Market Overview
5.3 Hospital Pharmacy
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Hospital Pharmacy: Geographic Segmentation Analysis
5.4 Retail Pharmacy
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Retail Pharmacy: Geographic Segmentation Analysis
5.5 Online Pharmacy
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Online Pharmacy: Geographic Segmentation Analysis
5.6 Others)
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Others) : Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Typhoid Fever Vaccines Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 EMERGENT (US)
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 BIO FARMA (INDONESIA)
6.4 BHARAT BIOTECH (INDIA)
6.5 BIO-MED (INDIA)
6.6 PFIZER INC. (US)
6.7 GLAXOSMITHKLINE PLC (UK)
6.8 NOVARTIS AG (SWITZERLAND)
6.9 MYLAN N.V. (US)
6.10 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
6.11 SANOFI (FRANCE)
6.12 ASTRAZENECA (UK)
6.13 JOHNSON & JOHNSON PRIVATE LIMITED (US)
6.14 MERCK & CO. INC. (US)
6.15 F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND)
6.16 BIOMÉRIEUX SA (FRANCE)
6.17 AMGEN INC. (US)
6.18 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JAPAN)
6.19 SUN PHARMACEUTICAL INDUSTRIES LTD. (INDIA)
6.20 LUPIN (INDIA)
6.21 MALLINCKRODT (US)
6.22 OTHER ACTIVE PLAYERS
Chapter 7: Global Typhoid Fever Vaccines Market By Region
7.1 Overview
7.2. North America Typhoid Fever Vaccines Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Live Attenuated Vaccine
7.2.4.2 Monovalent Typhoid Vaccines
7.2.4.3 Capsular Polysaccharide Vaccines
7.2.4.4 Conjugate Vaccine
7.2.4.5 Others)
7.2.4.6 Route of Administration (Oral
7.2.4.7 Parenteral)
7.2.4.8 End-Users (Hospitals
7.2.4.9 Specialty Clinics
7.2.4.10 Homecare
7.2.4.11 Others)
7.2.4.12
7.2.5 Historic and Forecasted Market Size By Distribution Channel
7.2.5.1 Hospital Pharmacy
7.2.5.2 Retail Pharmacy
7.2.5.3 Online Pharmacy
7.2.5.4 Others)
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Typhoid Fever Vaccines Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Live Attenuated Vaccine
7.3.4.2 Monovalent Typhoid Vaccines
7.3.4.3 Capsular Polysaccharide Vaccines
7.3.4.4 Conjugate Vaccine
7.3.4.5 Others)
7.3.4.6 Route of Administration (Oral
7.3.4.7 Parenteral)
7.3.4.8 End-Users (Hospitals
7.3.4.9 Specialty Clinics
7.3.4.10 Homecare
7.3.4.11 Others)
7.3.4.12
7.3.5 Historic and Forecasted Market Size By Distribution Channel
7.3.5.1 Hospital Pharmacy
7.3.5.2 Retail Pharmacy
7.3.5.3 Online Pharmacy
7.3.5.4 Others)
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Russia
7.3.6.2 Bulgaria
7.3.6.3 The Czech Republic
7.3.6.4 Hungary
7.3.6.5 Poland
7.3.6.6 Romania
7.3.6.7 Rest of Eastern Europe
7.4. Western Europe Typhoid Fever Vaccines Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Live Attenuated Vaccine
7.4.4.2 Monovalent Typhoid Vaccines
7.4.4.3 Capsular Polysaccharide Vaccines
7.4.4.4 Conjugate Vaccine
7.4.4.5 Others)
7.4.4.6 Route of Administration (Oral
7.4.4.7 Parenteral)
7.4.4.8 End-Users (Hospitals
7.4.4.9 Specialty Clinics
7.4.4.10 Homecare
7.4.4.11 Others)
7.4.4.12
7.4.5 Historic and Forecasted Market Size By Distribution Channel
7.4.5.1 Hospital Pharmacy
7.4.5.2 Retail Pharmacy
7.4.5.3 Online Pharmacy
7.4.5.4 Others)
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 The Netherlands
7.4.6.5 Italy
7.4.6.6 Spain
7.4.6.7 Rest of Western Europe
7.5. Asia Pacific Typhoid Fever Vaccines Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Live Attenuated Vaccine
7.5.4.2 Monovalent Typhoid Vaccines
7.5.4.3 Capsular Polysaccharide Vaccines
7.5.4.4 Conjugate Vaccine
7.5.4.5 Others)
7.5.4.6 Route of Administration (Oral
7.5.4.7 Parenteral)
7.5.4.8 End-Users (Hospitals
7.5.4.9 Specialty Clinics
7.5.4.10 Homecare
7.5.4.11 Others)
7.5.4.12
7.5.5 Historic and Forecasted Market Size By Distribution Channel
7.5.5.1 Hospital Pharmacy
7.5.5.2 Retail Pharmacy
7.5.5.3 Online Pharmacy
7.5.5.4 Others)
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Typhoid Fever Vaccines Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Live Attenuated Vaccine
7.6.4.2 Monovalent Typhoid Vaccines
7.6.4.3 Capsular Polysaccharide Vaccines
7.6.4.4 Conjugate Vaccine
7.6.4.5 Others)
7.6.4.6 Route of Administration (Oral
7.6.4.7 Parenteral)
7.6.4.8 End-Users (Hospitals
7.6.4.9 Specialty Clinics
7.6.4.10 Homecare
7.6.4.11 Others)
7.6.4.12
7.6.5 Historic and Forecasted Market Size By Distribution Channel
7.6.5.1 Hospital Pharmacy
7.6.5.2 Retail Pharmacy
7.6.5.3 Online Pharmacy
7.6.5.4 Others)
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkiye
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Typhoid Fever Vaccines Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Live Attenuated Vaccine
7.7.4.2 Monovalent Typhoid Vaccines
7.7.4.3 Capsular Polysaccharide Vaccines
7.7.4.4 Conjugate Vaccine
7.7.4.5 Others)
7.7.4.6 Route of Administration (Oral
7.7.4.7 Parenteral)
7.7.4.8 End-Users (Hospitals
7.7.4.9 Specialty Clinics
7.7.4.10 Homecare
7.7.4.11 Others)
7.7.4.12
7.7.5 Historic and Forecasted Market Size By Distribution Channel
7.7.5.1 Hospital Pharmacy
7.7.5.2 Retail Pharmacy
7.7.5.3 Online Pharmacy
7.7.5.4 Others)
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
|
Global Typhoid Fever Vaccines Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 3.41 Billion |
|
Forecast Period 2024-32 CAGR: |
12.7% |
Market Size in 2032: |
USD 10.00 Billion |
|
Segments Covered: |
By Type |
|
|
|
Route of Administration |
|
||
|
By End-Users |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
